MXCT insider buying & filings

← All candidates

MXCTMAXCYTE, INC.

NasdaqGS · Healthcare · $126.94M

$1.26

-0.79% · Sep 3

14 insider filings on record.
None of them an open-market buy in the last year.

Last Form 4 Aug 27 · scanned 5m ago

Price · 1Y · daily◆ 4 8-K

▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained

AI brief · from the filings on this pagePro

The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.

▸ Included with Pro →

Market cap

$126.94M

Float

93.7M

91% public

Short % float

Pro

Price / profit

—

not yet profitable

Price / future profit

—

Price / sales

4.1

The buyers

▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions

Director

Erck Stanley C

Bought $137.2K on Aug 13 — 100,000 sh @ $1.37, held direct, 25% of their stake.

0 of 1 position beat the S&P

median -37.0% vs S&P +6.4% same spans

Director

Douglas Richard

Bought $111.0K on Aug 13 — 80,000 sh @ $1.39, held direct, 35% of their stake.

0 of 1 position beat the S&P

median -37.0% vs S&P +6.4% same spans

President and CEO

Masoud Maher

Bought $102.9K on Aug 13 — 75,000 sh @ $1.37, held direct, 43% of their stake.

0 of 1 position beat the S&P

median -37.0% vs S&P +6.4% same spans

Institutional stakes

▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing

1 filingnewest first

13DRiver Global Investors LLP0.8%Aug 4

The record

newest first

DateTypeInsiderOf stakeShares @ priceValue

Aug 27SELLHemrajani RekhaDirectordirect10,684 @ $2.09$22.4K

Aug 13BUYSwirsky Douglas JCHIEF FINANCIAL OFFICER+31%direct50,000 @ $1.29$64.5K

Aug 13BUYMasoud MaherPresident and CEO+43%direct75,000 @ $1.37$102.9K

Aug 13BUYErck Stanley CDirector+25%direct100,000 @ $1.37$137.2K

Aug 13BUYDouglas RichardDirector+35%direct80,000 @ $1.39$111.0K

9 more transactions on Pro →

Context

Wall St

$4.11 avg target

+226.0% vs today · 4 analysts · consensus Strong Buy

▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice

Earnings · EPS vs forecast

2 of 3 quarters beat

Q4 '25−$0.06 act+$0.03

Q3 '25−$0.09 act+$0.01

Q2 '25−$0.12 act−$0.02

Coverage

Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for InvestorsInsider Monkey · 05-13 MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...GuruFocus.com · 05-13 MaxCyte Q1 Earnings Call HighlightsMarketBeat · 05-13 MaxCyte, Inc. Q1 2026 Earnings Call SummaryMoby · 05-13

The file stays open

15 filings on record.
The next one will be too.

All candidates

▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice

Erck Stanley C

Douglas Richard

Masoud Maher

15 filings on record.The next one will be too.

15 filings on record.
The next one will be too.